PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

Г

SUBMISSION TYPE:		NEW ASSIGNMENT					
NATURE OF CONVEYANCE:		ASSET TRANSFER AGREEMENT					
CONVEYING PARTY DATA							
Name Execution Date							
ILLUMIGEN BIOSCIENCES, INC. 11/10/2010							
RECEIVING PARTY DATA							
Name:	Name: IB SECURITYHOLDERS, LLC						
Street Address:	307 WESTLAKE AVENUE NORTH						
City:	SEATTLE						
State/Country:	WASHINGTON						
Postal Code:	Code: 98109						
PROPERTY NUMBERS Total: 1							
Property Type Number							
Application Number: 13302							
Application Number:	1330	2081	208				
CORRESPONDENCE	JL	2081	13302081				
CORRESPONDENCE	DATA 2063706001 be sent via US Mail 206.370.6641 suzanne.carte : C. Rachal Wii 925 Fourth Av Suite 2900	when the fax attempt is unsuccessful. er@klgates.com nger, Ph.D.	CH \$40.00				
CORRESPONDENCE Fax Number: <i>Correspondence will I</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2:	E DATA 2063706001 be sent via US Mail 206.370.6641 suzanne.carte : C. Rachal Wi 925 Fourth A Suite 2900 Seattle, WAS	when the fax attempt is unsuccessful. er@klgates.com nger, Ph.D. venue	\$40.00				
CORRESPONDENCE Fax Number: <i>Correspondence will I</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4:	E DATA 2063706001 be sent via US Mail 206.370.6641 suzanne.carte : C. Rachal Wii 925 Fourth Av Suite 2900 Seattle, WAS	when the fax attempt is unsuccessful. er@klgates.com nger, Ph.D. venue HINGTON 98104-1158	\$40.00				
CORRESPONDENCE Fax Number: <i>Correspondence will I</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET	E DATA 2063706001 be sent via US Mail 206.370.6641 suzanne.carte : C. Rachal Wii 925 Fourth Av Suite 2900 Seattle, WAS	when the fax attempt is unsuccessful. er@klgates.com nger, Ph.D. /enue HINGTON 98104-1158 2067833.00125	\$40.00				
CORRESPONDENCE Fax Number: <i>Correspondence will I</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET NAME OF SUBMITTE	E DATA 2063706001 be sent via US Mail 206.370.6641 suzanne.carte : C. Rachal Wii 925 Fourth Av Suite 2900 Seattle, WAS	when the fax attempt is unsuccessful. er@klgates.com nger, Ph.D. renue HINGTON 98104-1158 2067833.00125 C. Rachal Winger, Ph.D.	\$40.00				

502477490

source=Asset_Transfer_Agreement-Redacted-00125#page1.tif source=Asset_Transfer_Agreement-Redacted-00125#page2.tif source=Asset_Transfer_Agreement-Redacted-00125#page3.tif source=Asset_Transfer_Agreement-Redacted-00125#page4.tif source=Asset_Transfer_Agreement-Redacted-00125#page5.tif source=Asset_Transfer_Agreement-Redacted-00125#page6.tif source=Asset Transfer Agreement-Redacted-00125#page7.tif source=Asset_Transfer_Agreement-Redacted-00125#page8.tif source=Asset_Transfer_Agreement-Redacted-00125#page9.tif source=Asset Transfer Agreement-Redacted-00125#page10.tif source=Asset_Transfer_Agreement-Redacted-00125#page11.tif source=Asset_Transfer_Agreement-Redacted-00125#page12.tif source=Asset_Transfer_Agreement-Redacted-00125#page13.tif source=Asset Transfer Agreement-Redacted-00125#page14.tif source=Asset_Transfer_Agreement-Redacted-00125#page15.tif source=Asset_Transfer_Agreement-Redacted-00125#page16.tif source=Asset_Transfer_Agreement-Redacted-00125#page17.tif source=Asset_Transfer_Agreement-Redacted-00125#page18.tif source=Asset_Transfer_Agreement-Redacted-00125#page19.tif source=Asset_Transfer_Agreement-Redacted-00125#page20.tif

ASSET TRANSFER AGREEMENT

This ASSET TRANSFER AGREEMENT (this "<u>Agreement</u>"), dated as of November 10, 2010, is entered into by and among (i) **Cubist Pharmaceuticals, Inc.**, a Delaware corporation ("<u>Cubist</u>"), (ii) **Illumigen Biosciences, Inc.**, a Washington corporation and wholly-owned subsidiary of Cubist ("<u>Illumigen</u>"), and (iii) **IB Securityholders, LLC**, a Washington limited liability company ("<u>IBS</u>"). Cubist, Illumigen and IBS are referred to herein as the "<u>parties</u>" and each individually as a "<u>party</u>."

REDACTED

WHEREAS, Cubist and/or Illumigen is/are the owner(s) of the Transferred Assets (as defined herein); and

WHEREAS, Cubist and Illumigen wish to transfer to IBS, in satisfaction of the obligations of Cubist set forth in Section 6.10 of the Merger Agreement, all right, title and interest in and to the Transferred Assets, and IBS desires to acquire from Cubist and Illumigen all right, title and interest in and to the Transferred Assets.

NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

REDACTED

SECTION 2. PURCHASE AND SALE OF ASSETS.

2.1 <u>Assignment of Transferred Assets</u>. Subject to the terms and conditions of this Agreement, each of Cubist and Illumigen shall assign, transfer, convey and deliver to IBS, and IBS shall acquire and accept from Cubist and Illumigen at the Closing (as defined in <u>Section 2.2</u>), all right, title and interest throughout the world in and to the Transferred Assets. The assignment of the patents and patent applications included in the Transferred Assets shall be effected in part by delivery of a duly executed Patent Assignment in the form attached hereto as <u>Exhibit B</u> (the "<u>Patent Assignment</u>").

2.2 Closing.

REDACTED

(b) At the Closing, Cubist and Illumigen shall deliver, or cause to be delivered to IBS, the Patent Assignment, each executed by Cubist and Illumigen.

REDACTED

REDACTED

REDACTED

PATENT REEL: 031123 FRAME: 0586

C

REDACTED

REDACTED

REDACTED

REDACTED

[SIGNATURE PAGE FOLLOWS]

Signature Page to Asset Transfer Agreement

IN WITNESS WHEREOF each of the parties hereto has caused this Agreement to be executed as of the date set forth above by its duly authorized representatives.

CUBIST:

CUBIST PHARMACEUTICALS, INC.

By:

Name:Michael W. BonneyTitle:President and Chief Executive Officer

ILLUMIGEN:

ILLUMIGEN BJOSCHENCES, INC. By: Name: / Michael W Bonney Title: President

IBS:

IB SECURITYHOLDERS, LLC

By:___

Name: Charles L. Magness Title: Manager

IN WITNESS WHEREOF each of the parties hereto has caused this Agreement to be executed as of the date set forth above by its duly authorized representatives.

CUBIST:

CUBIST PHARMACEUTICALS, INC.

By:

Michael W. Bonney Name: Title: President and Chief Executive Officer

ILLUMIGEN:

ILLUMIGEN BIOSCIENCES, INC.

By:_

Name: Michael W. Bonney Title: President

IB SECURITYHOLDERS, LLC

By:

Name: Charles L. Magness Title: Manager

> PATENT REEL: 031123 FRAME: 0592

IBS:

EXHIBIT A

TRANSFERRED ASSETS

1. Patent Rights:

REDACTED

 2066721-103	US	12/061,548	02-Apr-2008	DETECTION OF MUTATIONS IN A	
				GENE ASSOCIATE WITH	
	,			RESISTANCE TO VIRAL	
				INFECTION, OAS1	

REDACTED

REDACTED

EXHIBIT B

PATENT ASSIGNMENT

[Attached]

ASSIGNMENT OF PATENTS

This Assignment of Patents, dated as of November 10, 2010, is by each of Cubist Pharmaceuticals, Inc., a Delaware corporation ("<u>Cubist</u>"), and Illumigen Biosciences, Inc., a Washington corporation and wholly-owned subsidiary of Cubist ("<u>Illumigen</u>" and together with Cubist, the "<u>Assignor</u>"), in each case solely to the extent that such party has an ownership interest in any Patent (as defined below) assigned hereby, to IB Securityholders, LLC, a Washington limited liability company (the "<u>Assignee</u>").

WHEREAS, Assignor is the owner of the patents and patent applications listed on <u>Exhibit A</u> attached hereto, including all foreign counterparts, divisions, continuations, continuations-in-part, reissues, reexaminations or supplemental patent certificates thereof or therefore (collectively, the "<u>Patents</u>");

WHEREAS, Assignor is assigning to Assignee all of Assignor's right title and interest in and to the Patents pursuant to an Asset Transfer Agreement executed contemporaneously herewith (the "Asset Transfer Agreement");

NOW, THEREFORE, in consideration of the premises set forth above and in the Asset Transfer Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged:

Assignor hereby sells, assigns, transfers, sets over and delivers to Assignee, Assignor's entire right, title and interest in and to the Patents, the same to be held and enjoyed by said Assignee, its successors, permitted assigns or legal representatives, together with income, royalties, damages or payments due on or after the date hereof, including, without limitation, all claims for damages or payments by reason of infringement or unauthorized use of the Patents, along with the right to sue for past infringements and collect same for Assignee's sole use and enjoyment.

Assignor further authorizes the Director of the United States Patent & Trademark Office, and any official of any country or countries foreign to the United States whose duty it is to record patents, applications and title thereto, to record the Patents and title thereto as the property of Assignee, its successors, legal representatives and assigns in accordance with the terms of this Assignment.

[Signature Page Follows]

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized representatives as a sealed instrument as of the date first written above:

CUBIST:

CUBIST PHARMACEUTICALS, INC. By Kam Michae W. Bonney Title: President and Chief Executive Officer

ILLUMIGEN:

ILLUMIGEN BIOSCHENCES, INC. By: Namez Michael W. Bonn President Title:

COMMONWEALTH OF MASSACHUSETTS)

COUNTY OF Middle Sec

)

)

Kunse she lotárv

My commission expires:

JANET I. MURPHY-KUROWSKI Notary Public Commonwealth of Massachusetts My Commission Expires September 23, 2010

RECORDED: 08/29/2013